| Primary |
| Infection Prophylaxis |
17.1% |
| Prophylaxis |
17.1% |
| Prophylaxis Against Graft Versus Host Disease |
8.2% |
| Graft Versus Host Disease |
7.7% |
| Drug Use For Unknown Indication |
6.5% |
| Thrombosis Prophylaxis |
6.1% |
| Multiple Sclerosis |
4.9% |
| Anxiety |
4.7% |
| Abdominal Pain |
3.7% |
| Hypertension |
2.8% |
| Prophylaxis Against Transplant Rejection |
2.8% |
| Immunosuppression |
2.6% |
| Antibiotic Prophylaxis |
2.3% |
| Liver Transplant |
2.3% |
| Renal Transplant |
2.3% |
| Antifungal Prophylaxis |
2.1% |
| Pain |
2.1% |
| Sedation |
1.9% |
| Anxiety Disorder |
1.4% |
| Bone Marrow Transplant |
1.4% |
|
| Pyrexia |
13.3% |
| Cytomegalovirus Infection |
10.0% |
| Sepsis |
6.7% |
| Toxoplasmosis |
6.7% |
| Urinary Tract Infection |
6.7% |
| Acute Respiratory Distress Syndrome |
5.0% |
| Human Herpesvirus 8 Infection |
5.0% |
| Renal Failure Acute |
5.0% |
| Transplant Rejection |
5.0% |
| Anaphylactic Shock |
3.3% |
| Bacterial Sepsis |
3.3% |
| Convulsion |
3.3% |
| Diarrhoea |
3.3% |
| Graft Dysfunction |
3.3% |
| Graft Versus Host Disease |
3.3% |
| Hepatic Enzyme Increased |
3.3% |
| Liver Transplant Rejection |
3.3% |
| Lung Disorder |
3.3% |
| Muscular Weakness |
3.3% |
| Myelodysplastic Syndrome |
3.3% |
|
| Secondary |
| Prophylaxis Against Transplant Rejection |
28.0% |
| Infection Prophylaxis |
12.5% |
| Renal Transplant |
10.1% |
| Prophylaxis |
9.9% |
| Antifungal Prophylaxis |
9.1% |
| Adult T-cell Lymphoma/leukaemia |
4.9% |
| Liver Transplant |
3.8% |
| Thrombosis Prophylaxis |
3.2% |
| Product Used For Unknown Indication |
2.8% |
| Prophylaxis Against Renal Transplant Rejection |
2.4% |
| Anxiety |
2.0% |
| Hypertension |
2.0% |
| Immunosuppression |
1.8% |
| Abdominal Pain |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Antibiotic Prophylaxis |
0.9% |
| Graft Versus Host Disease |
0.9% |
| Pain |
0.9% |
| Pemphigoid |
0.9% |
| Prophylaxis Against Graft Versus Host Disease |
0.9% |
|
| Transplant Rejection |
33.3% |
| Pyelonephritis |
6.9% |
| Pyrexia |
6.9% |
| Vomiting |
4.9% |
| Urinary Tract Infection |
4.2% |
| Bacterial Sepsis |
3.5% |
| Cytomegalovirus Infection |
3.5% |
| Diarrhoea |
3.5% |
| Ill-defined Disorder |
3.5% |
| Urosepsis |
3.5% |
| Ventricular Tachycardia |
3.5% |
| Pneumonia |
2.8% |
| Staphylococcal Infection |
2.8% |
| Therapeutic Agent Toxicity |
2.8% |
| Thrombotic Microangiopathy |
2.8% |
| Toxoplasmosis |
2.8% |
| White Blood Cell Count Decreased |
2.8% |
| Death |
2.1% |
| Graft Dysfunction |
2.1% |
| Human Herpesvirus 8 Infection |
2.1% |
|
| Concomitant |
| Prophylaxis Against Transplant Rejection |
58.8% |
| Immunosuppression |
7.1% |
| Renal Transplant |
6.8% |
| Liver Transplant |
4.2% |
| Prophylaxis Against Graft Versus Host Disease |
2.6% |
| Small Intestine Transplant |
2.6% |
| Stem Cell Transplant |
2.6% |
| Product Used For Unknown Indication |
1.9% |
| Immunosuppressant Drug Therapy |
1.6% |
| Anticoagulant Therapy |
1.3% |
| Drug Use For Unknown Indication |
1.3% |
| Hypertension |
1.3% |
| Kidney Transplant Rejection |
1.3% |
| Pancreas Islet Cell Transplant |
1.3% |
| Multiple Sclerosis |
1.0% |
| Osteopenia |
1.0% |
| Pancreas Transplant |
1.0% |
| Transplant Rejection |
1.0% |
| Antiviral Prophylaxis |
0.6% |
| Chronic Allograft Nephropathy |
0.6% |
|
| Kidney Transplant Rejection |
24.4% |
| Hepatic Fibrosis |
7.7% |
| Transplant Rejection |
7.7% |
| Pyrexia |
6.4% |
| Refusal Of Treatment By Patient |
6.4% |
| Sepsis |
5.1% |
| Gastrointestinal Haemorrhage |
3.8% |
| Parenteral Nutrition |
3.8% |
| Post Herpetic Neuralgia |
3.8% |
| Proteinuria |
3.8% |
| Venous Thrombosis |
3.8% |
| Acute Respiratory Distress Syndrome |
2.6% |
| Cardiac Arrest |
2.6% |
| Complications Of Transplanted Kidney |
2.6% |
| Death |
2.6% |
| Diabetes Mellitus Inadequate Control |
2.6% |
| Focal Glomerulosclerosis |
2.6% |
| Glomerular Filtration Rate Decreased |
2.6% |
| Glomerulonephritis Membranous |
2.6% |
| Graft Versus Host Disease |
2.6% |
|
